BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 247 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $546,850 | +32.2% | 3,753 | +7.6% | 0.02% | +60.0% |
| Q1 2022 | $413,691 | -78.8% | 3,489 | -75.4% | 0.02% | -44.4% |
| Q4 2021 | $1,951,114 | -3.4% | 14,158 | -2.6% | 0.03% | -6.9% |
| Q3 2021 | $2,019,335 | +126.3% | 14,537 | +11.4% | 0.03% | +123.1% |
| Q1 2021 | $892,309 | -22.9% | 13,055 | -3.3% | 0.01% | -23.5% |
| Q4 2020 | $1,157,514 | +10.1% | 13,505 | -6.0% | 0.02% | -10.5% |
| Q2 2020 | $1,050,883 | +100.0% | 14,374 | +14.1% | 0.02% | +111.1% |
| Q3 2019 | $525,505 | +15.2% | 12,596 | +21.0% | 0.01% | +12.5% |
| Q2 2019 | $455,985 | -14.9% | 10,413 | 0.0% | 0.01% | -20.0% |
| Q1 2019 | $535,957 | +39.2% | 10,413 | 0.0% | 0.01% | +25.0% |
| Q4 2018 | $385,073 | – | 10,413 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $107,867,000 | 52.60% |
| Knoll Capital Management, LLC | 856,844 | $83,182,000 | 43.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,082,555 | $202,174,000 | 27.86% |
| ARS Investment Partners, LLC | 558,286 | $54,198,000 | 5.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $17,113,000 | 4.52% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 401,006 | $38,930,000 | 4.51% |
| Eventide Asset Management | 1,990,797 | $193,267,000 | 2.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 56,626 | $5,497,000 | 2.45% |
| Avidity Partners Management LP | 882,500 | $85,673,000 | 2.32% |
| Nicholas Investment Partners, LP | 363,708 | $35,309,000 | 2.22% |